NCT01733121View on ClinicalTrials.gov

NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Tardive Dyskinesia
Interventions
DRUG

NBI-98854

25 mg capsule

DRUG

NBI-98854

50 mg capsule

DRUG

Placebo

Trial Locations (22)

19428

Conshohocken

19460

Phoenixville

21287

Baltimore

33012

Hialeah

33125

Miami

33486

Boca Raton

44122

Beachwood

44130

Middleburg Heights

48334

Farmington Hills

60640

Chicago

75062

Irving

75115

DeSoto

76021

Bedford

77008

Houston

77030

Houston

78229

San Antonio

80113

Englewood

92056

Oceanside

92626

Costa Mesa

92708

Fountain Valley

99352

Richland

00725

Caguas

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY